EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Quinazolinone‐Based Tumor‐Targeted Inhibitors

Jieming Li, Shuaiyi Lv, Bin Yang, Ruiping Ran, Yuanfang Kong iD, Juntao Cai, Guanglei Nan, Shiqing Jiang, Chunhong Dong

Chemistry & Biodiversity · 2026-06 · 23 (6)

DOI: 10.1002/cbdv.71413 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chemistry & Biodiversity, online erschienen am 11.06.2026. Verfasst von Jieming Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Henan University of Chinese Medicine, Zhengzhou, China. Hauptthemen laut MEDLINE: Quinazolinones, Antineoplastic Agents, Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 91 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quinazolinone derivatives, characterized by their unique heterocyclic scaffold and extensive structural tunability, hold considerable promise as targeted antitumor agents. This review systematically summarizes recent advances in the antitumor pharmacology, multifaceted mechanisms of action, and target inhibitor development of this compound class. Mechanistically, quinazolinone derivatives exert antitumor effects through multiple pathways, most prominently the potent inhibition of tyrosine kinases (e.g., EGFR and VEGFR), which is supported by extensive preclinical and clinical evidence. Additional mechanisms include downregulation of the PI3K/AKT/mTOR signaling axis, disruption of cell cycle progression, and interference with epigenetic regulatory proteins. These actions collectively lead to the blockade of tumor cell proliferation signals, induction of mitochondrial‐dependent apoptosis, and attenuation of tumor angiogenesis and metabolic reprogramming. Structure–activity relationship (SAR) studies show that adding specific substituents boosts both target selectivity and pharmacokinetic properties. Notably, novel derivatives with dual‐target synergy inhibit tumor growth and overcome drug resistance, offering new strategies against tumor heterogeneity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinazolinonesAntineoplastic AgentsNeoplasmsProtein Kinase InhibitorsHumansStructure-Activity RelationshipAnimalsCell ProliferationSignal Transduction

Stichwörter der Autor:innen

antitumor mechanismsmolecular targetspharmacological activitiesquinazolinone derivativesstructure–activity relationship

Substanzen

QuinazolinonesAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Henan University of Chinese Medicine, Zhengzhou, China.
  • Henan Key Laboratory of Chinese Medicine for Polysaccharides and Drugs Research, Zhengzhou, China.
  • Hefei Food and Drug Safety Inspection and Testing Center, Hefei, China.
  • The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.

ORCID-Profile: Yuanfang Kong

Förderung

  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Li, J., Lv, S., Yang, B., Ran, R., Kong, Y., Cai, J., Nan, G., Jiang, S., & Dong, C. (2026). Advances in Quinazolinone‐Based Tumor‐Targeted Inhibitors. Chemistry & Biodiversity, 23(6). https://doi.org/10.1002/cbdv.71413

Vancouver

Li J, Lv S, Yang B, Ran R, Kong Y, Cai J, et al. Advances in Quinazolinone‐Based Tumor‐Targeted Inhibitors. Chemistry & Biodiversity. 2026;23(6). doi:10.1002/cbdv.71413

BibTeX
@article{Li2026,
  author = {Li, Jieming and Lv, Shuaiyi and Yang, Bin and Ran, Ruiping and Kong, Yuanfang and Cai, Juntao and Nan, Guanglei and Jiang, Shiqing and Dong, Chunhong},
  title = {Advances in Quinazolinone‐Based Tumor‐Targeted Inhibitors},
  journal = {Chemistry & Biodiversity},
  year = {2026},
  volume = {23},
  number = {6},
  doi = {10.1002/cbdv.71413}
}
Kostenlos starten →